Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free OBD Stock Alerts

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.12 -0.01 (-4.00%)
As of 08/21/2026 05:50 AM Eastern
Compare

OBD vs. IXI, CLBX, APTA, NSCI, and FAB

Should you buy Oxford BioDynamics stock or one of its competitors? Oxford BioDynamics's main competitors and comparable companies include IXICO (IXI), Cellbxhealth (CLBX), Aptamer Group (APTA), NetScientific (NSCI), and Fusion Antibodies (FAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford BioDynamics compare to IXICO?

IXICO (LON:IXI) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

IXICO has higher revenue and earnings than Oxford BioDynamics. IXICO is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IXICO£7.28M2.20-£3.58M-£1.95N/A
Oxford BioDynamics£1.20M4.31-£103.52M-£0.20N/A

IXICO has a beta of 0.129, meaning that its stock price is 87% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

IXICO has a net margin of -24.98% compared to Oxford BioDynamics' net margin of -825.61%. IXICO's return on equity of -16.18% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
IXICO-24.98% -16.18% -10.40%
Oxford BioDynamics -825.61%-451.74%-56.23%

In the previous week, IXICO had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Oxford BioDynamics. IXICO's average media sentiment score of 0.75 beat Oxford BioDynamics' score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company Overall Sentiment
IXICO Positive
Oxford BioDynamics Neutral

13.0% of IXICO shares are owned by institutional investors. Comparatively, 11.6% of Oxford BioDynamics shares are owned by institutional investors. 3.1% of IXICO shares are owned by insiders. Comparatively, 15.6% of Oxford BioDynamics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

IXICO beats Oxford BioDynamics on 8 of the 13 factors compared between the two stocks.

How does Oxford BioDynamics compare to Cellbxhealth?

Oxford BioDynamics (LON:OBD) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

11.6% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
Cellbxhealth Neutral

Cellbxhealth has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M4.31-£103.52M-£0.20N/A
Cellbxhealth£1.15M12.61N/A-£3.49N/A

Cellbxhealth has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Cellbxhealth's return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Cellbxhealth N/A N/A N/A

Summary

Cellbxhealth beats Oxford BioDynamics on 5 of the 9 factors compared between the two stocks.

How does Oxford BioDynamics compare to Aptamer Group?

Aptamer Group (LON:APTA) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

3.3% of Aptamer Group shares are owned by institutional investors. Comparatively, 11.6% of Oxford BioDynamics shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by company insiders. Comparatively, 15.6% of Oxford BioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aptamer Group has a net margin of -178.52% compared to Oxford BioDynamics' net margin of -825.61%. Aptamer Group's return on equity of -135.35% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer Group-178.52% -135.35% -44.96%
Oxford BioDynamics -825.61%-451.74%-56.23%

Aptamer Group has higher revenue and earnings than Oxford BioDynamics. Aptamer Group is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.38M9.38-£14.17M-£0.11N/A
Oxford BioDynamics£1.20M4.31-£103.52M-£0.20N/A

In the previous week, Aptamer Group had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Aptamer Group and 0 mentions for Oxford BioDynamics. Aptamer Group's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Aptamer Group Neutral
Oxford BioDynamics Neutral

Aptamer Group has a beta of 0.899, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Summary

Aptamer Group beats Oxford BioDynamics on 9 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to NetScientific?

NetScientific (LON:NSCI) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

NetScientific has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
Oxford BioDynamics£1.20M4.31-£103.52M-£0.20N/A

In the previous week, NetScientific's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Oxford BioDynamics Neutral

14.7% of NetScientific shares are owned by institutional investors. Comparatively, 11.6% of Oxford BioDynamics shares are owned by institutional investors. 42.4% of NetScientific shares are owned by company insiders. Comparatively, 15.6% of Oxford BioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NetScientific has a net margin of -182.91% compared to Oxford BioDynamics' net margin of -825.61%. NetScientific's return on equity of -13.70% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Oxford BioDynamics -825.61%-451.74%-56.23%

NetScientific has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Summary

NetScientific beats Oxford BioDynamics on 9 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to Fusion Antibodies?

Oxford BioDynamics (LON:OBD) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

11.6% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Fusion Antibodies has a net margin of -91.92% compared to Oxford BioDynamics' net margin of -825.61%. Fusion Antibodies' return on equity of -210.32% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Fusion Antibodies -91.92%-210.32%-63.78%

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
Fusion Antibodies Neutral

Oxford BioDynamics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.224, suggesting that its stock price is 22% more volatile than the broader market.

Fusion Antibodies has higher revenue and earnings than Oxford BioDynamics. Fusion Antibodies is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M4.31-£103.52M-£0.20N/A
Fusion Antibodies£1.60M8.63-£4.10M-£1.50N/A

Summary

Fusion Antibodies beats Oxford BioDynamics on 6 of the 11 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

Export
MetricOxford BioDynamicsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£5.36M£4.01B£7.38B£2.54B
Dividend YieldN/A3.64%2.53%6.17%
P/E Ratio-0.6011.62272.60367.57
Price / Sales4.311,334.59623.3283,481.74
Price / Cash3.98105.1478.6227.89
Price / Book0.1516.8013.057.19
Net Income-£103.52M-£12.50M£3.47B£5.89B
7 Day Performance5.26%3.29%2.09%0.30%
1 Month Performance-14.29%8.23%6.63%3.31%
1 Year Performance-74.74%55.05%25.01%22.13%

Oxford BioDynamics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.12
-4.0%		N/A-74.7%£5.36M£1.20MN/A45
IXI
IXICO
N/AGBX 7.75
+3.3%		N/A-40.7%£16.97M£7.28MN/A89
CLBX
Cellbxhealth
N/AGBX 1.35
-0.4%		N/AN/A£15.29M£1.15MN/AN/A
APTA
Aptamer Group
N/AGBX 0.40
-5.9%		N/A-47.2%£13.82M£1.38MN/A37
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OBD) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel